Research & Development
Annovis Bio schedules corporate update webinar for next week
26 August 2026 - Annovis Bio Inc (NYSE:ANVS), a Phase 3 clinical-stage biotechnology company developing an investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer�...
Cellenkos' CK0803 granted US FDA Fast Track designation for ALS
26 August 2026 - Cellenkos Inc, a clinical-stage biotechnology company developing tissue-directed, cord blood-derived T-regulatory (Treg) cell therapies, announced on Tuesday that the US Food and Drug...
FDA approves Johnson & Johnson's IMAAVY (nipocalimab-aahu) to treat warm autoimmune haemolytic anaemia
25 August 2026 - Healthcare products company Johnson & Johnson (NYSE:JNJ) announced on Monday that the US Food and Drug Administration (FDA) has approved IMAAVY (nipocalimab-aahu) for the treatmen...
Labcorp to offer FDA-cleared pTau-217 blood test for Alzheimer's assessment
24 August 2026 - US laboratory services company Labcorp Holdings, Inc. (NYSE: LH) announced on Monday that, following US Food and Drug Administration clearance, it will offer the Elecsys pTau-217 test...
Tempus announces receipt of FDA clearance for AI pulmonary hypertension detection product
24 August 2026 - Medical technology company Tempus AI Inc (NASDAQ: TEM) reported on Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-PH, an AI-ena...
European Commission grants orphan designation for Vanda's imsidolimab
24 August 2026 - US biopharmaceutical company Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), said on Monday it has received European Commission orphan designation for imsidolimab, its investigational mono...